SELECT FROM MENU

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

Lung Cancer Summit

Where Leaders in Oncology Unite
Against Lung Cancer
||
To Share Knowledge
||
To Exchange
||
To Debate
||
To Advance Care
||
To Fight Cancer
||
To Drive Progress
||
To Provide Insights

CME-certified

Expert-Driven Education & Insights

ILCS 2026

Save the date and
join us next year
||
spread the word for 2026
||
join us for our next edition
||
mark your calendar

Int. Lung Cancer Summit 2026

Alfredo Addeo

Solange Peters

ADD THIS TO YOUR CALENDAR

Mark your calendar for the 2026 Intl. Lung Cancer Summit!
Building on the success of previous meetings, the ILCS will once again bring together a world-class faculty and audience to explore the latest advances across the full spectrum of lung cancer research and care. Whether you join us virtually or in person, save the date to make a difference for our patients.

For sponsoring opportunities, please contact us at sponsoring@lungsummit.org

CHUV-HUG Logo
ISREC
IASLC
ETOP
OncoViews

UPCOMING

Join us for
our roundtable in
||
latest advances in
||
your questions on
||
new therapies for
||
practice changes in
||
your patient cases in

LUNG CANCER — The Year In Review

Charles Rudin

USA

Solange Peters

Switzerland

Martin Reck

Germany

Agenda & Discussion Topics

DRUGGABLE SINCE 2025: New Approvals and Emerging Options

Solange Peters

The Year of SCLC: From hope to practice

Charles Rudin

Highlights in Targeted Therapies and ADCs

Martin Reck

2 CME Points

EACCME® & SGMO

Join our host, Solange Peters, for our Virtual Lung Summit on the newest advances in lung cancer care. This interdisciplinary session brings together leading experts to synthesize the most important findings of the past year and translate them into practical, real-world strategies. We’ll explore newly approved therapies, key updates in targeted treatments, and the evolving role of immunotherapy across NSCLC and SCLC. Don’t miss this opportunity to deepen your understanding, take part in the discussion, and come away with clear takeaways on the developments reshaping lung cancer treatment.
Register here

Do You Already Have An Account?
No need to sign up again: as a verified user, you will have access to all our sessions. Simply login to participate in this event.


First Time On Lung Summit?

SIGN UP NOW

This session is kindly supported by our partners with no influence on the content

Amgen
AstraZeneca
BeOne
Roche
PharmaMar
MSD

COMING SOON

Mark Your Calendar For Our
upcoming sessions
||
virtuals
||
CME-events
||
roundtables
||
webinars

Nicolas Girard

France

Jarushka Naidoo

Ireland

Oliver Gautschi

Switzerland

Solange Peters

Switzerland

Martin Reck

Germany

ILCS 2025

International Lung Cancer Summit 2025

ADD THIS TO YOUR CALENDAR

Following the success of the previous International Lung Cancer Summits (ILCS), we warmly invite you to the 7th edition, expertly chaired by the distinguished duo Solange Peters and Alfredo Addeo. This premier hybrid conference continues its tradition of excellence by highlighting the latest breakthroughs in lung cancer treatment. With a global lineup of renowned speakers from the USA, France, UK, Spain, Ireland, Italy, Australia, Singapore, and Switzerland, the ILCS provides a unique platform for professionals from clinics, universities, and research institutes to engage, network, and collaborate. By leveraging digital platforms, the summit fosters a dynamic environment for sharing insights and advancing lung cancer care.

CHUV-HUG Logo
ISREC
IASLC
ETOP
OncoViews

LED BY GLOBAL EXPERTS

Marius Ilié

France

Antonio Passaro

Italy

Antonio Calles

Spain

Xiuning Le

USA

Andrea Filippi

Italy

Noemi Reguart

Spain

Tom John

Australia

Alessandra Curioni

Switzerland

Patrick Forde

Ireland

Stephanie Saw

Singapore

Thomas Newsom-Davis

United Kingdom

Rami Manochakian

USA

ADD THIS TO YOUR CALENDAR

CHECK OUT OUR PROGRAM

CME Credits

26th September 2025

All times are in Central European Time

All Sessions Now Available on Demand

9.45

Welcome & Introduction by Chairs

Solange Peters & Alfredo Addeo

9.50

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

Marius Ilié (France)

10.10

TARGETING EGFR AND ALK IN NSCLC

Tom John (Australia)

10.35

OTHER ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

Stephanie Saw (Singapore)

11.20

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

  • ARGUING IN FAVOR OF AMIVANTAMAB + LAZERTINIB

    Xiuning Le (USA)
  • ARGUING IN FAVOR OF OSIMERTINIB + CHEMO

    Tom Newsom-Davis (UK)

11.50

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

Noemí Reguart (Spain)

14.15

TAILORING IO IN RESECTABLE NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

Patrick Forde (Ireland)

14.45

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

ANDREA R. FILIPPI (Italy)

15.30

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

Alessandra Curioni (Switzerland)

15.50

RESHAPING OUR APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LIMITED- AND EXTENSIVE-STAGE DISEASE

Rami Manochakian (USA)

16.20

Open Questions, Patient Cases & Guidelines

Panel Discussion With All

16.45

Closing Remarks by Chairs

Solange Peters & Alfredo Addeo
UEMS

THE ILCS IS INTERNATIONALLY ACCREDITED WITH 5 CME CREDITS, EACH BY:

  • EUROPEAN ACCREDITATION COUNCIL FOR CME (EACCME)
  • SWISS SOCIETY OF MEDICAL ONCOLOGY

EACCME credits can be converted to AMA PRA Cat. 1 Credits.

SGMO • SSOM • SSMO

Sponsors of ILCS 2025

MSD
Johnson & Johnson
PharmaMar
AstraZeneca
Amgen
Regeneron
Roche
Daiichi-Sankyo
Merck
BMS
BeOne
Gilead
Bayer
Pfizer
Summit Therapeutics
Takeda
AbbVie
The ILCS is supported by our partners, with no influence on the content.
For sponsoring opportunities, please contact us at sponsoring@lungsummit.org

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates